Diabetes & Endocrinology · page 2
Glargine gave no glycaemic edge over human insulin in low-resource type 1 care
A trial in Bangladesh and Tanzania found no advantage for insulin glargine over isophane. Weight returns at about 1 kg a month once semaglutide or tirzepatide stops. And metformin still does not prevent gestational diabetes.
Half the weight comes back within eight months of stopping a GLP-1
Pooled data from 1,776 people put regain at about a kilogram a month, with half the loss gone by seven and a half months. Plus glargine fails to beat isophane insulin in a low-resource trial, and weekly ketone testing turns out to be enough.
Metformin does not prevent gestational diabetes
Ten trials, 2,297 pregnancies, no reduction in gestational diabetes on the two commonest sets of criteria. Plus 25-year prevention data, an oral GLP-1 safety readout from Japan, and a quiet regulatory day.
Half of all gastroparesis sits in a diabetes clinic, and the drug list is where to start
A JAMA review puts type 2 diabetes behind 51.7% of gastroparesis cases and names GLP-1 agonists among the first drugs to stop. Plus survodutide's phase 3 result, why age at diagnosis outranks duration in childhood-onset type 1 diabetes, and two small trials whose numbers are too good to believe.
Oral GLP-1 safety data land, and every gestational diabetes subtype turns out to matter
A 52-week Japanese safety trial of oral orforglipron, ten-year follow-up showing all gestational diabetes subtypes carry a two- to three-fold later diabetes risk, and a genetic risk score that earns its place only in young children.
Once-weekly insulin plus GLP-1 beats daily glargine at insulin start
COMBINE 4 gives better HbA1c, weight and hypoglycaemia in one weekly injection. The Diabetes Prevention Program at 25 years says lifestyle, not metformin, holds down chronic disease. And Cochrane finds the case for bariatric surgery in diabetes rests on thinner evidence than most counselling assumes.
A once-weekly insulin-GLP-1 combination beats daily glargine, and the lipid goalposts move
COMBINE 4 shows once-weekly icodec plus semaglutide outperforming daily glargine on HbA1c, weight and hypoglycaemia. Meanwhile the 2026 dyslipidaemia guideline pulls millions of lower-risk adults into statin therapy, and two safety reviews sharpen what to watch on incretins and SGLT2 inhibitors.
Twenty-five years on, lifestyle kept the illnesses away and metformin did not
The Diabetes Prevention Program's Medicare follow-up finds a lasting cut in multimorbidity from lifestyle alone. A once-weekly insulin-plus-semaglutide combination beats daily glargine on HbA1c, weight and hypoglycaemia. And the 2026 lipid guideline makes 21.5 million more adults statin-eligible.
An oral GLP-1 finds its place on top of basal insulin
ACHIEVE-5 puts orforglipron alongside titrated glargine and cuts HbA1c by roughly a further percentage point. Finerenone's albuminuria benefit holds in type 1 diabetes regardless of glycaemic control.